Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus anlotinib in NSCLC
NCT04646330Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2020
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Nov 2020; status: completed.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04646330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646330.